title: Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.
abstract: Pemphigus vulgaris (PV) is an autoimmune blistering disease affecting the skin and mucous membranes. Rituximab, a CD20 chimeric monoclonal antibody, has efficacy in PV management. We report a case of severe oral PV that showed a progressive response to repeated courses of rituximab, culminating in a rapid response within 4 weeks following severe relapse 4 years after initial therapy. It demonstrates the progressively shorter time to achieve partial or complete remission following rituximab infusions, combined with minimal adjuvant therapy over a 7-year follow-up period.
authors.affiliation: Guys and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: D T
authors.initials: DT
authors.lastname: Greenblatt
authors.affiliation: Guys and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: E C
authors.initials: EC
authors.lastname: Benton
authors.affiliation: Guys and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: R W
authors.initials: RW
authors.lastname: Groves
authors.affiliation: Guys and St Thomas' NHS Foundation Trust, London, UK.
authors.forename: J F
authors.initials: JF
authors.lastname: Setterfield
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy*; D010392:Pemphigus / Q000188:drug therapy*; D000069283:Rituximab / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D000069283:Rituximab